CRDF
CRDF
NASDAQ · Biotechnology

Cardiff Oncology Inc

$1.60
+0.12 (+8.11%)
As of Feb 8, 2:11 PM ET ·
Analyst Consensus
Strong Buy
14
Analysts
Moderate
Coverage
Buy 12 86%
Hold 2 14%
Sell 0 0%
Price Target
Analyst Price Target +575.6% upside
Low Target $7.63
Average Target $10.81
High Target $13.89
Current Price $1.60
Current
$1.60
Target
$10.81
$7.63 $10.81 avg $13.89
Scenario Analysis
Bear Case
$7.63
376.9%
Low target
Base Case
$10.81
+575.6%
Avg target
Bull Case
$13.89
+768.1%
High target
Risk/Reward
2.0x
Favorable
Price in Context
52-Week High
$9.37
-82.9% from high
52-Week Low
$4.70
+-66.0% from low
Target vs 52W High
$10.81
+15.4% vs high
Next Earnings Report
Feb 26, 2026 · After Market Close
9d
until earnings
EPS Est: $-0.19
Earnings in 9 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%